Increasing Efficiency in the Pharma Analytical Workflow through Standards and Reference Materials

The mechanism of headspace SPME will be explained in detail.  Methods for enhancing extraction efficiency will be described. Advantages of headspace SPME over other common extraction methods will be highlighted.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Antibodies and Antibody-Drug Conjugate Higher Order Structures Revealed

RedShiftBio

Recently investigators have begun to harness new technology such as microfluidic modulation spectroscopy (MMS) to reveal protein structural changes, as a solid understanding of structure and function is extremely important to the effectiveness of biotherapeutic drugs and scientist today are challenged in gathering a complete understanding with current tools. During the biomanufacturing process, proteins such as antibodies, often undergo conformational changes that can alter their secondary structure, leading to critical variations in their overall function. These changes have been historically difficult to detect, as traditional analytical techniques are not great at detecting small differences in protein structure.
Watch Now

Deconstructing Powerful Drugs To Make Better Medicine

Psychedelic-class drugs like psilocybin, ketamine and MDMA are powerful probes of conscious states with tremendous promise for an array of psychiatric conditions. Each compound has a unique set of effects, some desirable and others less-so, often dependent on the setting in which they are given.
Watch Now

Successfully Digitalizing Drug Manufacturing

The COVID crisis has revealed the importance of rapid and optimized equipment design and scale up for drug and vaccine manufacturing processing as well as the necessity to maintain an optimal productivity level throughout the equipment lifecycle.
Watch Now

A Comprehensive Review of Biomarker Endpoints in In Vivo Models of Parkinson’s Disease

Charles River

Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Our scientists have validated available PD models for changes in fine motor skills, L-dopa-induced dyskinesias, drug-induced jaw movements, and non-motor endpoints such as cognition, constipation, and EDS. Additionally, we have also tested dopamine and other neurotransmitter levels in brain compartments of rodent and large animal models via microdialysis sampling.
Watch Now

Spotlight

resources